# A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies

> **NCT00719836** · PHASE1,PHASE2 · COMPLETED · sponsor: **S*BIO** · enrollment: 76 (actual)

## Conditions studied

- Acute Myelogenous Leukemia
- Chronic Myelogenous Leukemia
- Chronic Myelomonocytic Leukemia
- Myelodysplastic Syndromes
- Myelofibrosis

## Interventions

- **DRUG:** SB1518

## Key facts

- **NCT ID:** NCT00719836
- **Lead sponsor:** S*BIO
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2012-01
- **Final completion:** 2012-01
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2012-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00719836

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00719836, "A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00719836. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*